171 related articles for article (PubMed ID: 30365110)
41. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.
Schoofs G; Van Hout A; D'huys T; Schols D; Van Loy T
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29578516
[TBL] [Abstract][Full Text] [Related]
42. CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair.
Hu C; Yong X; Li C; Lü M; Liu D; Chen L; Hu J; Teng M; Zhang D; Fan Y; Liang G
J Surg Res; 2013 Jul; 183(1):427-34. PubMed ID: 23462453
[TBL] [Abstract][Full Text] [Related]
43. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.
Liang Z; Brooks J; Willard M; Liang K; Yoon Y; Kang S; Shim H
Biochem Biophys Res Commun; 2007 Aug; 359(3):716-22. PubMed ID: 17559806
[TBL] [Abstract][Full Text] [Related]
44. [Advance of research on SDF-1/CXCR4 axis and angiogenesis in leukemia--review].
Bao CH; He QT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):447-51. PubMed ID: 18426684
[TBL] [Abstract][Full Text] [Related]
45. Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.
Smith EW; Liu Y; Getschman AE; Peterson FC; Ziarek JJ; Li R; Volkman BF; Chen Y
J Med Chem; 2014 Nov; 57(22):9693-9. PubMed ID: 25356720
[TBL] [Abstract][Full Text] [Related]
46. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
47. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis.
Zhang F; Cui JY; Gao HF; Yu H; Gao FF; Chen JL; Chen L
Future Oncol; 2020 Nov; 16(32):2619-2633. PubMed ID: 32804554
[No Abstract] [Full Text] [Related]
48. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
Våbenø J; Haug BE; Rosenkilde MM
Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
[TBL] [Abstract][Full Text] [Related]
49. The role of CXCL12 in tumor microenvironment.
Meng W; Xue S; Chen Y
Gene; 2018 Jan; 641():105-110. PubMed ID: 29017963
[TBL] [Abstract][Full Text] [Related]
50. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
51. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
Oishi S; Fujii N
Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
[TBL] [Abstract][Full Text] [Related]
52. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.
Bhardwaj A; Srivastava SK; Singh S; Arora S; Tyagi N; Andrews J; McClellan S; Carter JE; Singh AP
Oncotarget; 2014 Nov; 5(22):11490-500. PubMed ID: 25359780
[TBL] [Abstract][Full Text] [Related]
53. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
54. Crosslinking-guided geometry of a complete CXC receptor-chemokine complex and the basis of chemokine subfamily selectivity.
Ngo T; Stephens BS; Gustavsson M; Holden LG; Abagyan R; Handel TM; Kufareva I
PLoS Biol; 2020 Apr; 18(4):e3000656. PubMed ID: 32271748
[TBL] [Abstract][Full Text] [Related]
55. Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4.
Tamamis P; Floudas CA
J Chem Inf Model; 2014 Apr; 54(4):1174-88. PubMed ID: 24660779
[TBL] [Abstract][Full Text] [Related]
56. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
57. Functional expression of CXCR4 in somatotrophs: CXCL12 activates GH gene, GH production and secretion, and cellular proliferation.
Lee Y; Kim JM; Lee EJ
J Endocrinol; 2008 Nov; 199(2):191-9. PubMed ID: 18753332
[TBL] [Abstract][Full Text] [Related]
58. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.
Beider K; Bitner H; Leiba M; Gutwein O; Koren-Michowitz M; Ostrovsky O; Abraham M; Wald H; Galun E; Peled A; Nagler A
Oncotarget; 2014 Nov; 5(22):11283-96. PubMed ID: 25526031
[TBL] [Abstract][Full Text] [Related]
59. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.
Ziarek JJ; Getschman AE; Butler SJ; Taleski D; Stephens B; Kufareva I; Handel TM; Payne RJ; Volkman BF
ACS Chem Biol; 2013 Sep; 8(9):1955-63. PubMed ID: 23802178
[TBL] [Abstract][Full Text] [Related]
60. Effect of TGF-β1/SDF-1/CXCR4 signal on BM-MSCs homing in rat heart of ischemia/perfusion injury.
Zhang SJ; Song XY; He M; Yu SB
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):899-905. PubMed ID: 27010148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
